Akanda Corp. ("Akanda" or the “Company”) (NASDAQ: AKAN), an
international medical cannabis platform company, today announced
that its UK import and distribution wholly-owned subsidiary CanMart
Ltd. (“CanMart”) has partnered with Phlo Connect and Cellen Life
Sciences (“Cellen”) to create a first-of-its-kind fully digital
dispensing collaboration for medical cannabis. The strategic
partnership strengthens CanMart’s existing partnership with
Cellen’s digital Leva Clinic and expands its route to market in the
UK with a dispensing model that is also fully digital while at the
same time improving the experience for UK medical cannabis
patients.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220628005777/en/
Phlo Connect integrates digitally with
CanMart, Akanda’s UK-based, fully licensed pharmaceutical importer
and distributor, to quickly and conveniently deliver prescriptions
to patients throughout the United Kingdom (Photo: Business
Wire)
Phlo Connect integrates digitally with CanMart, Akanda’s
UK-based, fully licensed pharmaceutical importer and distributor,
to quickly and conveniently deliver prescriptions to patients
throughout the United Kingdom. Initially, patients will secure
prescriptions through the Leva Clinic, with product transferred
through CanMart to Phlo Connect. Patients can then schedule
delivery to their home or office. Phlo Connect is the UK’s leading
API driven digital pharmacy infrastructure provider that seamlessly
connects prescribers, pharmacies and patients for an end-to-end
digital experience. Phlo Connect offers a 120-minute delivery
service in London and Birmingham and next-day delivery across the
UK. This process will be increasingly seamless for patients in the
near future as Phlo Connect, Leva Clinic, and CanMart build
additional digital interconnections.
“Akanda is committed to expanding access to high quality
products for anyone in need, and that is qualified in the United
Kingdom, a growing market for medical cannabis,” commented Tej
Virk, CEO of Akanda. “Phlo Connect and Cellen are the ideal
partners to make this happen, combining the UK’s first fully
digital pharmacy with a digital dispensing model that is easy to
use, secure, and real-time. Patients can arrange a specialist
consultation at www.levaclinic.com and seamlessly connect to Phlo
Connect’s smartphone app to arrange medical cannabis delivery. In
the nascent UK medical cannabis market, patients currently suffer
from excess friction as the prescription process, and last mile
delivery is disjointed. We firmly believe that our solution is the
best way to satisfy patients and get our 1P and 3P-supplied medical
cannabis in their hands quickly and conveniently, which will
greatly improve the patient experience.”
“We believe partnering with CanMart and Cellen will be a
game-changer for medicinal cannabis patients here in the UK. By
integrating with both CanMart and Cellen via our API driven
pharmacy platform, we believe that this partnership is the first
truly end to end digital experience for medicinal cannabis patients
in the UK,” commented Adam Hunter, CCO of Phlo Connect.
Added Eric Bystrom, CEO of Cellen, “Our patients require access
to new high-quality products without the friction and hassle of
traditional dispensing services. This partnership is another
example of our continuing efforts to build on our national,
established relationships with the wider pharmaceutical community
in innovative ways. We believe that CanMart’s access to high
quality products as well as Phlo Connect's extensive capabilities
in dispensing will go a long way to helping our service to our
patients.”
The digital dispensing solution is now live. Patients interested
in exploring the program should visit www.levaclinic.com to book a
free call with one of our specialists.
The partnership with Phlo Connect builds on CanMart’s existing
partnership with Cellen, a health tech company that provides
treatment to chronic pain patients through its digital pain clinic,
Leva Clinic, as well as through partners including the NHS, Boots
and others. The Leva Clinic, regulated by the Care Quality
Commission (“CQC”), is one of the first fully digital pain clinics
in the UK. Through a multi-disciplinary clinical team of expert
clinicians, clinical psychologists, physiotherapists and nurse
consultants, the Leva Clinic supports patients through personalized
online care plans. Cellen is also a medical cannabis supplier to
Project Twenty21, the large-scale medical cannabis observational
study monitored by Drug Science that aims to improve access to
medical cannabis for those in need.
Corporate Update
As previously announced, Harvinder Singh, Mohsen Rahimi,
Jatinder Dhaliwal and Katharyn Field joined Akanda’s board of
directors (the “Board”), effective June 23, 2022. Each of these new
directors brings with them a unique perspective within high growth
industries pertaining to supply chain, pharmaceuticals and
regulatory measures. Tej Virk continues to serve as Chief Executive
Officer of the Company and as part of the five-member Board.
Concluded Virk, “Along with the rest of the Akanda management
team, we wanted to extend our gratitude to the former directors for
their contributions to our business. The many contributions of our
prior Board members were critical in enabling us to reach this
inflection point. As we increase our focus on the European market,
and near-term opportunities, our new directors bring relevant
backgrounds and relationships. Management is excited to collaborate
with the new Board to achieve profitable growth. We have never been
more confident in Akanda’s future.”
About Akanda Corp.
Akanda is an international medical cannabis and wellness
platform company seeking to help people lead better lives through
improved access to high quality and affordable products. Akanda’s
portfolio includes Bophelo Bioscience & Wellness, a GACP
qualified cultivation campus in the Kingdom of Lesotho in Southern
Africa; Holigen, a Portugal-based cultivator, manufacturer and
distributor with a prized EU GMP certified indoor grow facility;
and CanMart, a UK-based fully licensed pharmaceutical importer and
distributor which supplies pharmacies and clinics within the UK.
The Company’s seed-to-patient supply chain also includes
partnerships with Cellen Life Sciences’ Leva Clinic, one of the
first fully digital pain clinics in the UK, and Cantourage, which
operates a platform for bringing medical cannabis to Europe.
Connect with Akanda: Email | Website | LinkedIn | Twitter |
Instagram
About Phlo
Phlo Connect is an API driven pharmacy infrastructure platform
that partners with other healthcare providers to offer a seamless
end to end digital pharmacy experience. Leveraging a network of
pharmacies, Phlo offers on-demand delivery of prescriptions at a
time and place which suits the patient. You can find out more about
Phlo’s infrastructure platform at www.phloconnect.com and its
on-demand pharmacy service at www.wearephlo.com.
Connect with Phlo: Email | Website | LinkedIn | Twitter |
Instagram
About Cellen
Cellen is a UK based healthcare innovation company, improving
the health and wellbeing of people living with chronic pain with a
focus on Medical Cannabis access. Founded in 2019 by Eric Bystrom
and Dr. Benjamin Viaris de Lesegno, Cellen is building integrated
solutions to manage chronic pain by combining clinical care,
innovation and real-world evidence generation. In November 2020,
Cellen launched Leva Clinic, the UK's first Care Quality Commission
(CQC) registered online pain clinic. Leva Clinic provides pain
management services to the NHS and Boots UK customers. Cellen was
selected as UK Department of International Trade's 25 'One's to
Watch' for Digital Health, was named a finalist for Tech Nations
Diversity and Inclusion Award 2021, and was awarded Outstanding for
Well-Led by the CQC in 2022.
Connect with Cellen: Email | Website | Twitter | Instagram
Cautionary Note Regarding
Forward-Looking Information and Statements
This press release contains certain "forward-looking
information" within the meaning of applicable Canadian securities
legislation and may also contain statements that may constitute
"forward-looking statements" within the meaning of the safe harbor
provisions of the United States Private Securities Litigation
Reform Act of 1995. Such forward-looking information and
forward-looking statements are not representative of historical
facts or information or current condition, but instead represent
only Akanda's beliefs regarding future events, plans or objectives,
many of which, by their nature, are inherently uncertain and
outside of Akanda's control. Generally, such forward-looking
information or forward-looking statements can be identified by the
use of forward-looking terminology such as "plans", "expects" or
"does not expect", "is expected", "budget", "scheduled",
"estimates", "forecasts", "intends", "anticipates" or "does not
anticipate", or "believes", or variations of such words and phrases
or may contain statements that certain actions, events or results
"may", "could", "would", "might" or "will be taken", "will
continue", "will occur" or "will be achieved". Forward-looking
information may relate to anticipated events or results including,
but not limited to business strategy, product development, market
changes and sales and growth plans. The forward-looking information
and forward-looking statements contained in this press release are
made as of the date of this press release, and Akanda does not
undertake to update any forward-looking information and/or
forward-looking statements that are contained or referenced herein,
except in accordance with applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220628005777/en/
Investor: Matt Chesler, CFA FNK IR ir@akandacorp.com
Media: United States: Annie Grant Allison + Partners
akanda@allisonpr.com Europe: Imogen Saunders Irvine Partners
imogen@irvinepartners.co.uk
Akanda (NASDAQ:AKAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akanda (NASDAQ:AKAN)
Historical Stock Chart
From Apr 2023 to Apr 2024